BNP as A Biomarker in Heart Disease

Advances in Clinical Chemistry

Volumn 40, Issue , 2005, Pages 1-36

  Vuolteenaho, Olli ^a   Ala Kopsala, Minna ^a   Ruskoaho, Heikki ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ANALYTICAL EQUIPMENT; BLOOD; HEART DISEASE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; REVIEW; STANDARD;

BIOLOGICAL MARKERS; HEART DISEASES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC;

EID: 33644812773     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(05)40001-3     Document Type: Review

References (168)

1. Sagnella G. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci 95 (1998) 519-529
2. Clerico A., Del Ry S., and Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: The need for a new generation of immunoassay methods. Clin Chem 46 (2000) 1529-1534
3. Hammerer-Lercher A., Puschendorf B., and Mair J. Cardiac natriuretic peptides: New laboratory parameters in heart failure patients. Clin Lab 47 (2001) 265-277
4. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocrine Reviews 24 (2003) 341-356
5. de Bold A., Bruneau B., and Kurowski de Bold M. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 31 (1996) 7-18
6. Goetze J. Biochemistry of pro-B-type natriuretic peptide-derived peptides: The endocrine heart revisited. Clin Chem 50 (2004) 1503-1510
7. de Bold A., Borenstein H., Veress A., and Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28 (1981) 89-94
8. Flynn T., de Bold M., and de Bold A. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun 117 (1983) 859-865
9. Sudoh T., Kangawa K., Minamino N., and Matsuo H. A new natriuretic peptide in porcine brain. Nature 332 (1988) 78-81
10. Ogawa Y., Nakao K., Mukoyama M., et al. Rat brain natriuretic peptide-tissue distribution and molecular form. Endocrinology 126 (1990) 2225-2227
11. Ogawa Y., Nakao K., Mukoyama M., et al. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res 69 (1991) 491-500
12. Totsune K., Takahashi K., Ohneda M., Itoi K., Murakami O., and Mouri T. C-type natriuretic peptide in the human central nervous system: Distribution and molecular form. Peptides 15 (1994) 37-40
13. Minamino N., Aburaya M., Kojima M., Miyamoto K., Kangawa K., and Matsuo H. Distribution of C-type natriuretic peptide and its messenger RNA in rat central nervous system and peripheral tissue. Biochem Biophys Res Commun 197 (1993) 326-335
14. Takei Y. Structural and functional evolution of the natriuretic peptide system in vertebrates. Int Rev Cytol 194 (2000) 1-66
15. Inoue K., Naruse K., Yamagami S., Mitani H., Suzuki N., and Takei Y. Four functionally distinct C-type natriuretic peptides found in fish reveal evolutionary history of the natriuretic peptide system. Proc Natl Acad Sci USA 100 (2003) 10079-10084
16. Sudoh T., Maekawa K., Kojima M., Minamino N., Kangawa K., and Matsuo H. Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide. Biochem Biophys Res Commun 159 (1989) 1427-1434
17. Ruskoaho H. Atrial natriuretic peptide: Synthesis, release, and metabolism. Pharmacol Rev 44 (1992) 479-602
18. Thibault G., Amiri F., and Garcia R. Regulation of natriuretic peptide secretion by the heart. Annu Rev Physiol 61 (1999) 193-217
19. Mäntymaa P., Vuolteenaho O., Marttila M., and Ruskoaho H. Atrial stretch induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expression in vitro. Endocrinology 133 (1993) 1470-1473
20. Magga J., Vuolteenaho O., Tokola H., Marttila M., and Ruskoaho H. Involvement of transcriptional and posttranscriptional mechanisms in cardiac overload-induced increase of B-type natriuretic peptide gene expression. Circ Res 81 (1997) 694-702
21. Tokola H., Hautala N., Marttila M., et al. Mechanical load-induced alterations in B-type natriuretic peptide gene expression. Can J Physiol Pharmacol 79 (2001) 646-653
22. Ruskoaho H., Kinnunen P., Taskinen T., Vuolteenaho O., Leppäluoto J., and Takala T. Regulation of ventricular atrial natriuretic peptide release in hypertrophied rat myocardium. Effects of exercise. Circulation 80 (1989) 390-400
23. Thibault G., Nemer M., Drouin J., et al. Ventricles as a major site of atrial natriuretic factor synthesis and release in cardiomyopathic hamsters with heart failure. Circ Res 65 (1989) 71-82
24. Sugden P., and Clerk A. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 83 (1998) 345-352
25. Petrich B., and Wang Y. Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. Trends Cardiovasc Med 14 (2004) 50-55
26. Tenhunen O., Sarman B., Kerkelä R., et al. Mitogen-activated protein kinases p38 and ERK 1/2 mediate the wall stress-induced activation of GATA-4 binding in adult heart. J Biol Chem 279 (2004) 24852-24860
27. Tavi P., Laine M., Weckström M., and Ruskoaho H. Cardiac mechanotransduction: From sensing to disease and treatment. Trends Pharmacol Sci 22 (2001) 254-260
28. Chun Y., Hyun J., Kwak Y., et al. Hypoxic activation of the atrial natriuretic peptide gene promoter through direct and indirect actions of hypoxia-inducible factor-1. Biochem J 370 (2003) 149-157
29. Klinger J., Warburton R., Pietras L., et al. Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 282 (2002) H58-H65
30. Jessup M., and Brozena S. Heart failure. N Engl J Med 348 (2003) 2007-2018
31. Eichhorn E., and Bristow M. Medical therapy can improve the biological properties of the chronically failing heart: A new era in the treatment of heart failure. Circulation 94 (1996) 2285-2296
32. Wolk R. Arrhythmogenic mechanisms in left ventricular hypertrophy. Europace 2 (2000) 216-223
33. Cameron V., Rademaker M., Ellmers L., Espiner E., Nicholls M., and Richards A. Atrial (ANP) and brain natriuretic peptide (BNP) expression after myocardial infarction in sheep: ANP is synthesized by fibroblasts infiltrating the infarct. Endocrinology 141 (2000) 4690-4697
34. Gardner D. Natriuretic peptides: Markers or modulators of cardiac hypertrophy?. Trends Endocrinol Metab 14 (2003) 411-416
35. Stein B., and Levin R. Natriuretic peptides: Physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 135 (1998) 914-923
36. Tamura N., Ogawa Y., Chusho H., et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 97 (2000) 4239-4244
37. Ogawa Y., Tamura N., Chusho H., and Nakao K. Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. Can J Physiol Pharmacol 79 (2001) 723-729
38. Tsuruda T., Boerrigter G., Huntley B., et al. Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 91 (2002) 1127-1134
39. Koller K., and Goeddel D. Molecular biology of the natriuretic peptides and their receptors. Circulation 86 (1992) 1081-1088
40. Tamura N., Chrisman T., and Garbers D. The regulation and physiological roles of the guanylyl cyclase receptors. Endocr J 48 (2001) 611-634
41. Kuhn M. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res 93 (2003) 700-709
42. Tremblay J., Desjardins R., Hum D., Gutkowska J., and Hamet P. Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases. Mol Cell Biochem 230 (2002) 31-47
43. Turner A., and Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J 11 (1997) 355-364
44. Yan W., Wu F., Morser J., and Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA 97 (2000) 8525-8529
45. Knappe S., Wu F., Madlansacay M., and Wu Q. Identification of domain structures in the propeptide of corin essential for the processing of proatrial natriuretic peptide. J Biol Chem 279 (2004) 34464-34471
46. Sawada Y., Suda M., Yokoyama H., et al. Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin. J Biol Chem 272 (1997) 20545-20554
47. Baertschi A., Monnier D., Schmidt U., Levitan E., Fakan S., and Roatti A. Acid prohormone sequence determines size, shape, and docking of secretory vesicles in atrial myocytes. Circ Res 89 (2001) E23-E29
48. Seidler T., Pemberton C., Yandle T., Espiner E., Nicholls G., and Richards M. The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiled-coil motifs. Biochem Biophys Res Commun 255 (1999) 495-501
49. De Lemos J., Morrow D., Bentley J., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
50. Daly C., Fox K., and Henein M. Natriuretic peptides in the diagnosis of heart disease-first amongst equals?. Int J Cardiol 84 (2002) 107-113
51. Ala-Kopsala M., Ruskoaho H., Leppäluoto J., et al. Single Assay for Amino-Terminal Fragments of Cardiac A- and B-Type Natriuretic Peptides. Clin Chem. 51 (2005) 708-714
52. Clerico A., and Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: A review. Clin Chem 50 (2004) 33-50
53. Hammerer-Lercher A., Ludwig W., Falkensammer G., et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: Effects of assays on diagnostic performance of markers. Clin Chem 50 (2004) 1174-1183
54. Yandle T., Fisher S., Espiner E., Richards M., and Nicholls G. Validating aminoterminal BNP assays: A word of caution. Lancet 353 (1999) 1068-1069
55. Ala-Kopsala M., Magga J., Peuhkurinen K., et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 50 (2004) 1576-1588
56. Hunt P., Richards A., Nicholls M., Yandle T., Doughty R., and Espiner E. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment. Clin Endocrinol (Oxf) 47 (1997) 287-296
57. Mueller T., Gegenhuber A., Poelz W., and Haltmayer M. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: Implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem 49 (2003) 976-979
58. Kono M., Yamaguchi A., and Tsuji T. An immunoradiometric assay for brain natriuretic peptide in human plasma. Kaku Igaku 13 (1993) 2-7
59. Shionogi & Co. Home Page. http://www.shionogi.co.jp/index_e.html/
60. Bayer Diagnostics Home Page. http://www.bayerdiag.com/
61. Biosite Inc. Home Page. http://www.biosite.com/
62. Abbott Diagnostics Home Page. http://www.abbottdiagnostics.com/
63. Collinson P., Barnes S., Gaze D., Galasko G., Lahiri A., and Senior R. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 6 (2004) 365-368
64. Roche Diagnostics Home Page. http://www.roche-diagnostics.com/
65. Missbichler A., Hawa G., Woloszczuk W., Schmal N., and Hartter E. Enzyme immunoassays for proBNP fragments (8-29) and (32-57). J Lab Med 23 (1999) 241-244
66. Biomedica Medizinprodukte Gmbh & Co. Home Page. http://www.bmgrp.com/probnp.html
67. Prontera C., Emdin M., Zucchelli G., Ripoli A., Passino C., and Clerico A. Natriuretic peptides (NPs): Automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. Clin Chem 49 (2003) 1552-1554
68. Seino Y., Ogawa A., Yamashita T., et al. Application of NT-proBNP and BNP measurements in cardiac care: A more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 6 (2004) 295-300
69. Mueller T., Gegenhuber A., Poelz W., and Haltmayer M. Biochemical diagnosis of impaired left ventricular ejection fraction-comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP). Clin Chem Lab Med 42 (2004) 159-163
70. Mueller T., Gegenhuber A., Poelz W., and Haltmayer M. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 341 (2004) 41-48
71. Prontera C., Emdin M., Zucchelli G., Ripoli A., Passino C., and Clerico A. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: Comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 42 (2004) 37-44
72. Pfister R., Scholz M., Wielckens K., Erdmann E., and Schneider C. Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail 6 (2004) 289-293
73. Vasan R., Larson M., Benjamin E., Evans J., Reiss C., and Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort. J Am Coll Cardiol 33 (1999) 1948-1955
74. Mir T., Marohn S., Laer S., Eiselt M., Grollmus O., and Weil J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 110 (2002) e76
75. Alehagen U., Lindstedt G., Eriksson H., and Dahlström U. Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. Clin Chem 49 (2003) 1337-1346
76. Wright S., Doughty R., Pearl A., et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: A randomized, controlled trial. J Am Coll Cardiol 42 (2003) 1793-1800
77. Mueller T., Gegenhuber A., Poelz W., and Haltmayer M. Preliminary evaluation of the AxSYM B-type natriuretic peptide (BNP) assay and comparison with the ADVIA Centaur BNP assay. Clin Chem 50 (2004) 1104-1106
78. Yeo K., Wu A., Apple F., et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 338 (2003) 107-115
79. Mueller T., Gegenhuber A., Poelz W., and Haltmayer M. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: Implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem 49 (2003) 976-979
80. Cannon C., McCabe C., Wilcox R., et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 102 (2000) 149-156
81. Sabatine M., Morrow D., de Lemos J., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: Simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
82. Cannon C., Weintraub W., Demopoulos L., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 (2001) 1879-1887
83. Morrow D., de Lemos J., Sabatine M., et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 41 (2003) 1264-1272
84. Morrow D., de Lemos J., Sabatine M., et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 41 (2003) 1852 . Erratum in:
85. Antman E., Louwerenburg H., Baars H., et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 105 (2002) 1642-1649
86. Antman E., Louwerenburg H., Baars H., et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 105 (2002) 2799 . Erratum in:
87. Mega J., Morrow D., De Lemos J., et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: An ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 44 (2004) 335-339
88. Sadanandan S., Cannon C., Chekuri K., et al. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 44 (2004) 564-568
89. Karl J., Borgya A., Gallusser A., et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 230 (1999) 177-181
90. Omland T., Persson A., Ng L., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002) 2913-2918
91. Richards A., Nicholls M., Espiner E., et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107 (2003) 2786-2792
92. Morita E., Yasue H., Yoshimura M., et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88 (1993) 82-91
93. Suzuki S., Yoshimura M., Nakayama M., et al. Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: A long-term follow-up analysis. Circulation 110 (2004) 1387-1391
94. Berger R., Huelsman M., Strecker K., et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105 (2002) 2392-2397
95. Anand I., Fisher L., Chiang Y., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
96. Uusimaa P., Ruskoaho H., Vuolteenaho O., et al. Plasma vasoactive peptides after acute myocardial infarction in relation to left ventricular dysfunction. Int J Cardiol 69 (1999) 5-14
97. Gill D., Seidler T., Troughton R., et al. Vigorous response in plasma N-terminal pro-brain natriuretic peptide (NT-BNP) to acute myocardial infarction. Clin Sci (Lond) 106 (2004) 135-139
98. FRISC-II Study Group. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during Instability in Coronary artery disease Investigators. Lancet 354 (1999) 708-715
99. James S., Lindahl B., Siegbahn A., et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108 (2003) 275-281
100. Magga J., Puhakka M., Hietakorpi S., et al. Atrial natriuretic peptide, B-type natriuretic peptide, and serum collagen markers after acute myocardial infarction. J Appl Physiol 96 (2004) 1306-1311
101. Galvani M., Ferrini D., and Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail 6 (2004) 327-333
102. Morrison L., Harrison A., Krishnaswamy P., Kazanegra R., Clopton P., and Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 39 (2002) 202-209
103. Bayes-Genis A., Santalo-Bel M., Zapico-Muniz E., et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 6 (2004) 301-308
104. Knudsen C., Riis J., Finsen A., et al. Diagnostic value of a rapid test for B-type natriuretic peptide in patients presenting with acute dyspnoe: Effect of age and gender. Eur J Heart Fail 6 (2004) 55-62
105. Redfield M., Rodeheffer R., Jacobsen S., Mahoney D., Bailey K., and Burnett Jr. J. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: A community-based study. Circulation 109 (2004) 3176-3181
106. McCullough P., Nowak R., McCord J., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106 (2002) 416-422
107. Maisel A., Clopton P., Krishnaswamy P., et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: Results from the Breathing Not Properly (BNP) multinational study. Am Heart J 147 (2004) 1078-1084
108. Logeart D., Saudubray C., Beyne P., et al. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol 40 (2002) 1794-1800
109. Teboul A., Gaffinel A., Meune C., Greffet A., Sauval P., and Carli P. Management of acute dyspnea: Use and feasibility of brain natriuretic peptide (BNP) assay in the prehospital setting. Resuscitation 61 (2004) 91-96
110. Knudsen C., Omland T., Clopton P., et al. Diagnostic value of B-Type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. Am J Med 116 (2004) 363-368
111. Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350 (2004) 647-654
112. McDonagh T., Morrison C., Lawrence A., et al. Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population. Lancet 350 (1997) 829-833
113. Davis R., Hobbs F., Kenkre J., et al. Prevalence of left ventricular systolic dysfunction and heart failure in high-risk patients: Community based epidemiological study. BMJ 325 (2002) 1156-1160
114. Hunt S., Baker D., Chin M., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38 (2001) 2101-2113
115. Remme W., and Swedberg K. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22 (2001) 1527-1560 . Erratum in:
116. Remme W., and Swedberg K. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22 (2001) 2217-2218
117. Cardarelli R., and Lumicao Jr. T. B-type natriuretic peptide: A review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians. J Am Board Fam Pract 16 (2003) 327-333
118. Richards A. The natriuretic peptides in heart failure. Basic Res Cardiol 99 (2004) 94-100
119. Dao Q., Krishnaswamy P., Kazanegra R., et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 37 (2001) 379-385
120. Koglin J., Pehlivanli S., Schwaiblmair M., Vogeser M., Cremer P., and vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 38 (2001) 1934-1941
121. Cohn J., and Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
122. Stevenson W., Stevenson L., Middlekauff H., and Saxon L. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation 88 (1993) 2953-2961
123. Connolly S., Hallstrom A., Cappato R., et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs. Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 21 (2000) 2071-2078
124. Hobbs F., Davis R., Roalfe A., Hare R., Davies M., and Kenkre J. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: Cohort study in representative and high-risk community populations. BMJ 324 (2002) 1498-1502
125. McDonagh T., Holmer S., Raymond I., Luchner A., Hildebrant P., and Dargie H. NT-proBNP and the diagnosis of heart failure: A pooled analysis of three European epidemiological studies. Eur J Heart Fail 6 (2004) 269-273
126. Doust J., Glasziou P., Pietrzak E., and Dobson A. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 164 (2004) 1978-1984
127. Wilson J., Hanamanthu S., Chomsky D., and Davis S. Relationship between exertional symptoms and functional capacity in patients with heart failure. J Am Coll Cardiol 33 (1999) 1943-1947
128. Krüger S., Graf J., Kunz D., Stickel T., Hanrath P., and Janssens U. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol 40 (2002) 718-722
129. Tang W., Girod J., Lee M., et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 108 (2003) 2964-2966
130. Logeart D., Thabut G., Jourdain P., et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of readmission after decompensated heart failure. J Am Coll Cardiol 43 (2004) 635-641
131. Dokainish H., Zoghbi W., Lakkis N., Quinones M., and Nagueh S. Comparative accuracy of B-type natriuretic peptide and tissue Doppler echocardiography in the diagnosis of congestive heart failure. Am J Cardiol 93 (2004) 1130-1135
132. Johnson W., Omland T., Hall C., et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39 (2002) 1623-1629
133. Troughton R., Frampton C., Yandle T., Espiner E., Nicholls M., and Richards A. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
134. Troughton R., Frampton C., Yandle T., Espiner E., Nicholls G., and Richards M. Plasma amino-terminal B-type natriuretic peptide measured by Elecsys 2010 assay in a trial of hormone-guided treatment for heart failure. Clin Chem 49 (2003) 1212-1215
135. Kawai K., Hata K., Takaoka H., Kawai H., and Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: A potential of hormone-guided treatment. Am Heart J 141 (2001) 925-932
136. Nicholls M., Lainchbury J., Richards A., Troughton R., and Yandle T. Brain natriuretic peptide-guided therapy for heart failure. Ann Med 33 (2001) 422-427
137. Richards A., Lainchbury J., Nicholls M., Troughton R., and Yandle T. BNP in hormone-guided treatment of heart failure. Trends Endocrinol Metab 13 (2002) 151-155
138. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273 (1995) 1450-1456
139. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 274 (1995) 462 . Erratum in:
140. McClure S., Caruana L., Davie A., Goldthorp S., and McMurray J. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ 317 (1998) 516-519
141. McDonagh T., Cunningham A., Morrison C., et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 86 (2001) 21-26
142. Groenning B., Nilsson J., Sondergaard L., et al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J 143 (2002) 923-929
143. Nielsen O., McDonagh T., Robb S., and Dargie H. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 41 (2003) 113-120
144. Mottram P., Leano R., and Marwick T. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol 92 (2003) 1434-1438
145. Sutton T., Stewart R., Gerber I., et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 41 (2003) 2280-2287
146. Qi W., Mathisen P., Kjekshus J., et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 142 (2001) 725-732
147. Qi W., Mathisen P., Kjekshus J., et al. The effect of aortic valve replacement on N-terminal natriuretic propeptides in patients with aortic stenosis. Clin Cardiol 25 (2002) 174-180
148. Pellikka P., Nishimura R., Bailey K., and Tajik A. The natural history of adults with asymptomatic, hemodynamically significant aortic stenosis. J Am Coll Cardiol 15 (1990) 1012-1017
149. Gerber I., Stewart R., Legget M., et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 107 (2003) 1884-1890
150. Watanabe M., Murakami M., Furukawa H., and Nakahara H. Is measurement of plasma brain natriuretic peptide levels a useful test to detect for surgical timing of valve disease?. Int J Cardiol 96 (2004) 21-24
151. Gerber I., Stewart R., French J., et al. Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation. Am J Cardiol 92 (2003) 755-758
152. Gerber I., Stewart R., French J., et al. Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation. Am J Cardiol 93 (2004) 526 . Erratum in:
153. Cowley C., Bradley J., and Shaddy R. B-type natriuretic peptide levels in congenital heart disease. Pediatr Cardiol 25 (2004) 336-340
154. Maron B. Hypertrophic cardiomyopathy: A systematic review. JAMA 287 (2002) 1308-1320
155. Maron B., Tholakanahalli V., Zenovich A., et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 109 (2004) 984-989
156. Freitag M., Larson M., Levy D., et al. Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham Heart Study. Hypertension 41 (2003) 978-983
157. Hildebrandt P., Boesen M., Olsen M., Wachtell K., and Groenning B. N-terminal pro brain natriuretic peptide in arterial hypertension-a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 6 (2004) 313-317
158. Sever P., Dahlöf B., Poulter N., et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 19 (2001) 1139-1147
159. Uusimaa P., Tokola H., Ylitalo A., et al. Plasma B-type natriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertension. Int J Cardiol 97 (2004) 251-256
160. Nagaya N., Nishikimi T., Okano Y., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 31 (1998) 202-208
161. Sandoval J., Bauerle O., Palomar A., et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 89 (1994) 1733-1744
162. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865-870
163. Ribeiro A., Lindmarker P., Juhlin-Dannfelt A., Johnsson H., and Jorfeldt L. Echocardiography Doppler in pulmonary embolism: Right ventricular dysfunction as a predictor of mortality rate. Am Heart J 134 (1997) 479-487
164. ten Wolde M., Tulevski I., Mulder J., et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 107 (2003) 2082-2084
165. Kyle R., and Gertz M. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 32 (1995) 45-59
166. Palladini G., Campana C., Klersy C., et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107 (2003) 2440-2445
167. Rossi A., Enriquez-Sarano M., Burnett Jr. J., Lerman A., Abel M., and Seward J. Natriuretic peptide levels in atrial fibrillation: A prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 35 (2000) 1256-1262
168. Ylitalo K., Uusimaa P., Vuolteenaho O., Ruskoaho H., and Peuhkurinen K. Vasoactive peptide release in relation to hemodynamic and metabolic changes during rapid ventricular pacing. Pacing Clin Electrophysiol 22 (1999) 1064-1070